Nine Chapters Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Nine Chapters Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$27K	Buy	+12,500	New	+$30.5K	0.06%	148
2014 Q4	–	Sell	-1,550	Closed	-$66K	–	1385
2014 Q3	$66K	Buy	+1,550	New	+$83.2K	0.01%	953
2014 Q1	–	Sell	-3,910	Closed	-$220K	–	1103
2013 Q4	$220K	Buy	+3,910	New	+$220K	0.02%	692

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nine Chapters Capital Management's OREX Position: Q3 2017 in Review

Nine Chapters Capital Management opened a new position in Orexigen Therapeutics, Inc. (OREX) in Q3 2017: 12,500 shares worth $27K. The stake represents 0.06% of the portfolio and ranks #148 among its holdings. This is a return to the name: Nine Chapters Capital Management previously reported a position in OREX as recently as Q3 2014.

Nine Chapters Capital Management first reported a position in OREX in Q4 2013 and has held it in 3 quarters since. The position peaked at $220K in Q4 2013. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

Nine Chapters Capital Management held 12,500 shares of Orexigen Therapeutics, Inc. worth $27K as of Q3 2017.
Orexigen Therapeutics, Inc. was a new Nine Chapters Capital Management position in Q3 2017.
Orexigen Therapeutics, Inc. made up 0.06% of Nine Chapters Capital Management's portfolio in Q3 2017, its #148 holding.
Nine Chapters Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and has held it in 3 quarters since.
Nine Chapters Capital Management's Orexigen Therapeutics, Inc. position peaked at $220K in Q4 2013.
42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.